Myxredlin FDA Approval History
FDA Approved: Yes (First approved June 20, 2019)
Brand name: Myxredlin
Generic name: insulin human in sodium chloride
Dosage form: Injection
Company: Baxter International Inc.
Treatment for: Diabetes, Type 1, Diabetes, Type 2
Myxredlin (insulin human in sodium chloride) is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
Development Timeline for Myxredlin
|Jul 22, 2019||Baxter Announces U.S FDA Approval of Myxredlin, the First and Only Ready-To-Use Insulin for IV Infusion|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.